Page last updated: 2024-11-10

nalbuphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311304
CHEMBL ID895
CHEBI ID7454
SCHEMBL ID3766
MeSH IDM0014433

Synonyms (58)

Synonym
BIDD:GT0060
CHEBI:7454 ,
nalbuphinum
nalbufina
17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
BRD-K66404838-003-03-8
(4r,4as,7s,7ar,12bs)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
gtpl1663
(5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol
PRESTWICK3_000118
BSPBIO_000136
PRESTWICK2_000118
nalbuphine
20594-83-6
C07251
DB00844
n-cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol
NCGC00162275-02
17-(cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol
einecs 243-901-6
morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5alpha,6alpha)-
nalbuphinum [inn-latin]
nalbuphine [inn:ban]
nalbufina [dcit]
PRESTWICK0_000118
SPBIO_002075
PRESTWICK1_000118
BPBIO1_000150
HMS2089I04
intapan
CHEMBL895 ,
D08246
intapan (tn)
nalbuphine (inn)
bdbm50105085
NCGC00179652-02
dtxcid103345
dtxsid8023345 ,
cas-20594-83-6
tox21_112008
unii-l2t84iqi2k
l2t84iqi2k ,
nalbuphine [who-dd]
nalbuphine [inn]
17-(cyclobutylmethyl)-4,5.alpha.-epoxymorphinan-3,6.alpha.,14-triol
nalbuphine [mi]
nalbuphine [vandf]
morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-
SCHEMBL3766
NETZHAKZCGBWSS-CEDHKZHLSA-N
(1s,5r,13r,14s,17s)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,14,17-triol
(-)-17-(cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol
Q277979
NCGC00179652-04
EN300-19631168
(1s,5r,13r,14s,17s)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,14,17-triol
nalbuphin
nalbuphinum (inn-latin)

Research Excerpts

Overview

Nalbuphine is a synthetic opioid with comparable analgesic activity to morphine but with a better safety profile. It is an effective adjuvant to 0.5% ropivacaine in ultrasound-guided supraclavicular BPB and is a reasonable alternative to sufentanil when used in PCIA.

ExcerptReferenceRelevance
"Nalbuphine is a safe and effective kappa agonist adjuvant."( Comparison of fentanyl and nalbuphine as adjuvants to intrathecal 0.5% bupivacaine in lower limb surgeries: A randomised double-blind prospective study.
Charitha, K; Durga, P; Geetha, S; Kar, P; Rudrakshala, S, 2023
)
1.93
"Nalbuphine is a synthetic opioid with comparable analgesic activity to morphine but with a better safety profile. "( Comparative pharmacokinetics of nalbuphine nasal spray and solution for injection in healthy volunteers.
Kovalova, KV; Kuznetsov, IE; Mashchenko, SV; Oliinykov, DS; Tsapko, GV; Tymko, VG, 2023
)
2.64
"Nalbuphine is an effective adjuvant to 0.5% ropivacaine in ultrasound-guided supraclavicular BPB. "( Efficacy of Nalbuphine as an Adjuvant to Ropivacaine in Ultrasound-guided Supraclavicular Brachial Block: A Prospective Randomized Controlled Study.
Kalika, P; Ran, R; Xiao, Y; Xue, R; Zhen, M; Zheng, J, 2020
)
2.38
"And nalbuphine is a reasonable alternative to sufentanil when used in PCIA."( The 95% effective dose of nalbuphine in patient-controlled intravenous analgesia for patients undergoing laparoscopic total hysterectomy compared to equivalent sufentanil.
Sun, Z; Yang, G; Zheng, H; Zhu, Z, 2020
)
1.34
"Nalbuphine (NLB) is a kappa-agonist and mu-partial antagonist, widely used for opioid withdrawal de-addiction, opioid-induced pruritis and as emergent analgesia."( Submental nalbuphine exhibits improved efficacy in ameliorating acute pain in prehospital emergent conditions; a comparative study with conventional intramuscular using gamma scintigraphy.
Bhatnagar, A; Chorsiya, V; Choudhary, S; Karwasra, R; Khanna, K; Nagpal, P; Nishad, DK; Popli, H; Sharma, D; Sharma, N, 2020
)
2.4
"Nalbuphine (NLB) is an approved, inexpensive, non-controlled, opioid agonist/antagonist analgesic used worldwide in various clinical settings for pain management."( Intranasal solid lipid nanoparticles for management of pain: A full factorial design approach, characterization & Gamma Scintigraphy.
Bhatnagar, A; Hasan, N; Jain, GK; Karwasra, R; Khan, N; Khanna, K; Khanna, S; Kumar, A; Nishad, DK; Popli, H; Rawat, S; Sharma, N, 2021
)
1.34
"Nalbuphine is a semi-synthetic opioid indicated for the relief of moderate to severe pain. "( Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation.
Chern, WH; Huang, JD; Huang, WC; Kuo, HY; Tai, L; Tien, YE; Uang, YS, 2017
)
2.21
"Nalbuphine is a semi-synthetic opioid indicated for the relief of moderate to severe pain. "( In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release.
Chern, WH; Huang, JD; Ku, MY; Li, CJ; Lu, CY; Tien, YE, 2017
)
2.18
"Nalbuphine is a potentially effective opioid analgesic for mice that is not currently classified as a controlled substance."( Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.
Kick, BL; Shu, P; Sun, D; Taylor, DK; Wen, B, 2017
)
1.47
"Nalbuphine is a μ-opioid antagonist and κ-opioid agonist."( A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.
Crawford, PW; Hait, H; Kumar, J; Mathur, VS; Sciascia, T, 2017
)
1.41
"Nalbuphine, is a mu receptor antagonist and a ĸappa receptor agonist."( Effect of adding nalbuphine to intrathecal bupivacaine with morphine on postoperative nausea and vomiting and pruritus after elective cesarean delivery: a randomized double blinded study.
Abdelaziz, MR; Aly, MG; Ibrahim, AS; Thabet, ME, 2019
)
1.57
"Nalbuphine is an agonist of κ-opioid receptors and a partial agonist of μ-opioid receptors, which can stimulate κ-receptors and antagonize the acute rewarding effects of morphine. "( Chronic co-administration of nalbuphine attenuates the development of opioid dependence.
Dhawan, A; Jain, R; Kumar, P; Raghav, R; Roy, TS, 2018
)
2.21
"Nalbuphine is an effective substitute for butorphanol, providing another option if butorphanol is unavailable due to shortage, controlled status or cost, without requiring a change in anesthetic workflow."( Use of nalbuphine as a substitute for butorphanol in combination with dexmedetomidine and tiletamine/zolazepam: a randomized non-inferiority trial.
Cornell, HN; Hofmeister, EH; Kelsey, SE; Kreisler, RE; Smith, VA, 2020
)
1.73
"Nalbuphine is a nearly ideal opioid for this purpose due to its unique pharmacological properties as a μ-receptor antagonist/κ-receptor agonist and a high safety profile."( [Nalbuphine in pediatric anesthesia].
Becke, K; Schultz-Machata, AM; Weiss, M, 2014
)
2.03
"Nalbuphine (NAL) is a potent opioid analgesic, but can only be administered by injection. "( Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.
Ho, ST; Hsiong, CH; Hu, OY; Huang, PW; Lin, MJ; Shih, TY; Wang, HJ, 2014
)
2.07
"Nalbuphine is an inexpensive, non-controlled, opioid analgesic that has been in clinical use for decades. "( Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice.
Narver, HL, 2015
)
3.3
"Nalbuphine is an agonist-antagonist opioid. "( The use of nalbuphine in paediatric anaesthesia.
Kubica-Cielińska, A; Zielińska, M, 2015
)
2.25
"Nalbuphine is an opioid analgesic agent widely used for control of mild-to-severe pain. "( Population pharmacokinetics of nalbuphine after surgery in children.
Bressolle, F; Capdevila, X; Dadure, C; Khier, S; Kinowski, JM; Rochette, A, 2011
)
2.1
"Nalbuphine is a parenteral opioid which effectively treats pain and may cause less ACS."( The impact of parenteral narcotic choice in the development of acute chest syndrome in sickle cell disease.
Britton, K; DeBaun, M; Lewing, K; Woods, G, 2011
)
1.09
"Nalbuphine is a mixed opioid agonist-antagonist and has been reported to be effective in treating opioid-induced pruritus."( Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after cesarean delivery.
Chang, CS; Chang, YL; Liao, CC; Sheen, MJ; Tsai, SC; Tseng, CH; Wong, SY,
)
1.15
"Nalbuphine is an opioid-analgesic with agonist-antagonist properties. "( The analgesic effect of nalbuphine and its long-acting prodrug, nalbuphine pivalate, in rats.
Chen, KT; Chen, YW; Ho, ST; Hu, OY; Wang, JJ, 2002
)
2.06
"Nalbuphine is an ideal supplementary analgesic drug for midazolam-induced conscious sedation during operative endoscopy because it has no cardiovascular effect and only a moderate depressive effect on respiration. "( Effect of nalbuphine on the motility of the sphincter of Oddi in patients with suspected sphincter of Oddi dysfunction.
Bertalan, V; Lonovics, J; Madácsy, L; Szepes, A, 2003
)
2.16
"Nalbuphine is an inexpensive opioid and currently is not a controlled substance in the U.S."( The sedative and behavioral effects of nalbuphine in dogs.
Gaynor, JS; Hellyer, PW; Lester, PA; Mama, K; Wagner, AE, 2003
)
1.31
"Nalbuphine (Nubain) is a mixed action mu-kappa agonist used clinically for the management of pain. "( Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers.
Goletiani, NV; Mello, NK; Mendelson, JH; Sholar, MB; Siegel, AJ; Skupny, A, 2007
)
2.17
"Nalbuphine is an agonist/antagonist analgesic. "( Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
Errick, JK; Heel, RC, 1983
)
3.15
"Nalbuphine proved to be a good analgetic, not statistically different from morphine but having statistically significantly fewer side effects."( [Analgesia and adverse effects of nalbuphine (Nubain) in comparison with morphine following hysterectomy].
Alon, E; Hossli, G; Krayer, S, 1984
)
1.27
"Nalbuphine (EN2234A) is an agonist-antagonist analgesic. "( Comparison of the calming and sedative effects of nalbuphine and pentazocine for paediatric premedication.
Goodarzi, M; Rita, L; Seleny, F, 1980
)
1.96
"Nalbuphine hydrochloride is an opioid agonist-antagonist that has gained acceptance as a pre-hospital analgesic agent. "( Excessive morphine requirements after pre-hospital nalbuphine analgesia.
Flapan, AD; Houlihan, KP; Mitchell, RG; Steedman, DJ, 1999
)
2
"Nalbuphine is a mixed opioid agonist/antagonist analgesic. "( Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
Pasternak, GW; Paul, D; Pick, CG, 1992
)
3.17
"Nalbuphine is a mixed opioid agonist/antagonist, the analgesic properties of which are still open to debate. "( Nalbuphine does not act analgetically in electrical painful tooth pulp stimulation in man.
Arndt, JO; Klement, W; Medert, HA, 1992
)
3.17
"Nalbuphine appears to be a disappointing agent for epidural use after Caesarean delivery."( Epidural nalbuphine for analgesia following caesarean delivery: dose-response and effect of local anaesthetic choice.
Camann, WR; Datta, S; Gilbertson, LI; Hurley, RH; Long, ML, 1991
)
1.42
"Nalbuphine is a potent semisynthetic agonist/antagonist analgesic."( Efficacy of nalbuphine as a parenteral analgesic for the treatment of painful episodes in children with sickle cell disease.
Parson, PM; Strickland, DK; Woods, GM, 1990
)
1.38
"Nalbuphine is a new partly agonistic antagonistic opioid, that may offer some advantages especially in postoperative pain relief. "( [Nalbuphine as compared with pethidine for postoperative pain therapy].
Luger, TJ; Mitterschiffthaler, G; Morawetz, RF; Theiner, A; Wieser, C, 1990
)
2.63
"Nalbuphine is a good choice for postoperative pain."( Comparison of intramuscular nalbuphine and nicomorphine in the treatment of post-operative pain.
Admiraal, PV; Wozniak, S, 1989
)
1.29
"Nalbuphine is a new agonist and antagonist opioid analgesic agent that undergoes an important hepatic metabolism. "( Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.
Bergnieres, J; Blondel, Y; Gardin, ME; Grippat, JC; Jaillon, P; Lecocq, B; Meignan, S; Richard, MO; Vergnoux, O, 1989
)
2.04
"Nalbuphine is a potent agonist/antagonist analgesic with a low side effect profile and low abuse potential. "( Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
De Souza, EB; Kuhar, MJ; Schmidt, WK, 1988
)
3.16
"Nalbuphine is a satisfactory alternative to morphine for post-orchidopexy pain and may offer the advantages of greater safety and convenience."( A comparison of nalbuphine with morphine for post-orchidopexy pain.
Wandless, JG, 1987
)
1.34
"Nalbuphine is a potent analgesic with a low side effect and dependence profile in animals and man. "( Nalbuphine.
Clark, R; Schmidt, WK; Shotzberger, GS; Smith, DH; Tam, SW; Vernier, VG, 1985
)
3.15
"Nalbuphine is an agonist-antagonist analgesic chemically related to the opiate agonist oxymorphone and to the opiate antagonist naloxone. "( Nalbuphine's reversal of hypovolemic shock in the anesthetized rat.
Anselmo, DM; McKenzie, JE; Muldoon, SM, 1985
)
3.15
"Nalbuphine is a newer drug which, like pentazocine, is an opioid agonist-antagonist."( Nalbuphine and pentazocine in an opioid-benzodiazepine sedative technique: a double-blind comparison.
Bell, PF; Graham, JL; McCaughey, W, 1988
)
2.44
"Nalbuphine is an effective opioid antagonist after fentanyl anesthesia, but its use is associated with side effects, and analgesia for the post-sternotomy patient may be unsatisfactory unless the dose is carefully titrated to the minimum required to antagonize respiratory depression."( Nalbuphine antagonism of fentanyl-induced ventilatory depression: a randomized trial.
Finlayson, DC; Hug, CC; Jaffe, RS; Kopel, ME; Moldenhauer, CC; Tobia, V, 1988
)
2.44
"Nalbuphine was found to be a satisfactory analgesic adjuvant in this anesthetic technique."( A double-blind study of the respiratory effects of nalbuphine hydrochloride in spontaneously breathing anesthetized patients.
O'Connor, SA; Wilkinson, DJ, 1988
)
1.25
"Nalbuphine is a useful postoperative analgesic, as effective as pethidine."( Self-administered nalbuphine, morphine and pethidine. Comparison, by intravenous route, following cholecystectomy.
Bahar, M; Rosen, M; Vickers, MD, 1985
)
1.32

Effects

Nalbuphine pivalate has a very long duration of analgesic action. Has a stimulatory effect on sphincter of Oddi motility.

Nalbuphine has equal analgesic properties to morphine, has a low addiction potential, and can be stored and administered without restrictions, unlike morphine. It has been shown to effectively antagonize the respiratory depressant activity of narcotic analgesics while concomitantly adding to their analgetic responses. Nal Buphine pivalate has a very long duration of analgesic action.

ExcerptReferenceRelevance
"Nalbuphine pivalate has a very long duration of analgesic action. "( The analgesic effect of nalbuphine and its long-acting prodrug, nalbuphine pivalate, in rats.
Chen, KT; Chen, YW; Ho, ST; Hu, OY; Wang, JJ, 2002
)
2.06
"Nalbuphine has a stimulatory effect on sphincter of Oddi motility in patients with a suspected sphincter of Oddi dysfunction. "( Effect of nalbuphine on the motility of the sphincter of Oddi in patients with suspected sphincter of Oddi dysfunction.
Bertalan, V; Lonovics, J; Madácsy, L; Szepes, A, 2003
)
2.16
"Nalbuphine has been increasingly used as a local anesthetic adjuvant to extend the duration of analgesia in brachial plexus block (BPB)."( Efficacy of Nalbuphine as a Local Anesthetic Adjuvant for Brachial Plexus Block: A Systematic Review and Meta-analysis.
Cheng, X; Jiang, J; Zhang, D; Zhou, C, 2022
)
2.54
"Nalbuphine has been suggested to be used for post-cesarean section (CS) intravenous analgesia. "( A comparative study of three concentrations of intravenous nalbuphine combined with hydromorphone for post-cesarean delivery analgesia.
Chen, XZ; Huang, CY; Li, SX; Xu, LL; Yang, MJ, 2020
)
2.24
"Nalbuphine has been commercially available for 40 years for the treatment of acute pain; few studies have centered on management of chronic pain. "( Does nalbuphine have a niche in managing pain?
Davis, MP; Fernandez, C; McPherson, ML; Regel, S,
)
2.09
"Nalbuphine pivalate has a very long duration of analgesic action. "( The analgesic effect of nalbuphine and its long-acting prodrug, nalbuphine pivalate, in rats.
Chen, KT; Chen, YW; Ho, ST; Hu, OY; Wang, JJ, 2002
)
2.06
"Nalbuphine has a stimulatory effect on sphincter of Oddi motility in patients with a suspected sphincter of Oddi dysfunction. "( Effect of nalbuphine on the motility of the sphincter of Oddi in patients with suspected sphincter of Oddi dysfunction.
Bertalan, V; Lonovics, J; Madácsy, L; Szepes, A, 2003
)
2.16
"Nalbuphine has few effects on cardiovascular hemodynamics in patients without cardiac disease or with stable ischemic disease."( Evaluation of nalbuphine hydrochloride.
Miller, RR, 1980
)
1.34
"Nalbuphine has equal analgesic properties to morphine, has a low addiction potential, and can be stored and administered without restrictions, unlike morphine."( Excessive morphine requirements after pre-hospital nalbuphine analgesia.
Flapan, AD; Houlihan, KP; Mitchell, RG; Steedman, DJ, 1999
)
1.28
"Nalbuphine has been shown to effectively antagonize the respiratory depressant activity of narcotic analgesics while concomitantly adding to their analgetic responses."( Nalbuphine.
Clark, R; Schmidt, WK; Shotzberger, GS; Smith, DH; Tam, SW; Vernier, VG, 1985
)
2.43

Actions

Nalbuphine was found to produce significantly less inhibition of gastrointestinal activity than any of the clinically useful narcotic or agonist/antagonist analgesics tested in animals. It stimulated LCGU in nuclei of the spinal tract of the trigeminal nerve and in the globus pallidus.

ExcerptReferenceRelevance
"Nalbuphine did not produce these effects, but stimulated LCGU in nuclei of the spinal tract of the trigeminal nerve and in the globus pallidus."( Differential effects of mu and kappa opioid analgesics on cerebral glucose utilization in the rat.
Fanelli, RJ; Jasinski, DR; London, ED; Szikszay, M, 1987
)
0.99
"Nalbuphine did not produce these effects, but stimulated LCGU in nuclei of the spinal trigeminal tract."( Effects of opioid analgesics on local cerebral glucose utilization.
Fanelli, R; Jasinski, D; London, E; Szikszay, M, 1986
)
0.99
"Nalbuphine was found to produce significantly less inhibition of gastrointestinal activity than any of the clinically useful narcotic or agonist/antagonist analgesics tested in animals."( Nalbuphine.
Clark, R; Schmidt, WK; Shotzberger, GS; Smith, DH; Tam, SW; Vernier, VG, 1985
)
2.43

Treatment

Nalbuphine-treated group had higher levels of aspartate aminotransferase and hydroxybutyric acid dehydrogenase but not creatine phosphokinase. Pretreatment with nal Buphine (1.0-2.0 mg/kg s.c.) did not alter the antinociceptive effect of either morphine or nalBuphine measured 3 h later.

ExcerptReferenceRelevance
"The nalbuphine-treated group had higher levels of aspartate aminotransferase and hydroxybutyric acid dehydrogenase but not creatine phosphokinase."( Experience with nalbuphine, a new opioid analgesic, in acute myocardial infarction.
Greenbaum, RA; Kaye, G; Mason, PD, 1987
)
1.1
"Pretreatment with nalbuphine failed to alter the inhibitory effect of morphine as well as that of nalbuphine."( The effects of morphine and nalbuphine on intestinal transit in mice.
Wong, CL, 1984
)
0.89
"Pretreatment with nalbuphine (1.0-2.0 mg/kg s.c.) did not alter the antinociceptive effect of either morphine or nalbuphine measured 3 h later, while naloxone effect was more effective in antagonizing the antinociceptive actions of morphine and nalbuphine."( Increased naloxone potency induced by pretreatment with morphine and nalbuphine in mice.
Wai, MK; Wong, CL,
)
0.69

Toxicity

Small doses of intrathecal nalbuphine produce fewer adverse effects, such as pruritus and postoperative nausea and vomiting, compared with intratheCal morphine. However, when morphine and nal Buphine are mixed together, the clinical interactions in different combining ratios on analgesic effect and adverse events are unknown.

ExcerptReferenceRelevance
"05 mg/kg to provide a safe outpatient intravenous sedative technique."( Nalbuphine combined with midazolam for outpatient sedation. An assessment of safety in volunteers.
Cole, PV; Sury, MR, 1988
)
1.72
" It has been shown that N is a safe agent which has no considerable effect on respiration, hemodynamics, blood gas composition, and metabolism."( [The evaluation of the efficacy and safety of using nalbuphine hydrochloride (Nubain) in patients in the early postoperative period].
Chizhov, AI; Egorova, IA; Lebedeva, RN; Nikoda, VV; Petrov, RO; Poroĭkova, MV; Sandrikov, VA; Vinnitskiĭ, LI,
)
0.38
"We performed a prospective, randomized, double-blinded, multicenter study to compare the analgesic efficacy and adverse effects of intrathecal nalbuphine, at three different doses, and intrathecal morphine for postoperative pain relief after cesarean deliveries."( Advantages of intrathecal nalbuphine, compared with intrathecal morphine, after cesarean delivery: an evaluation of postoperative analgesia and adverse effects.
Culebras, X; Gaggero, G; Kern, C; Marti, RA; Zatloukal, J, 2000
)
0.81
"Small doses of intrathecal nalbuphine produce fewer adverse effects, such as pruritus and postoperative nausea and vomiting, compared with intrathecal morphine."( Advantages of intrathecal nalbuphine, compared with intrathecal morphine, after cesarean delivery: an evaluation of postoperative analgesia and adverse effects.
Culebras, X; Gaggero, G; Kern, C; Marti, RA; Zatloukal, J, 2000
)
0.9
" PCBs using 1% lidocaine injected superficially should be considered a safe and effective form of obstetric analgesia."( Is paracervical block safe and effective? A prospective study of its association with neonatal umbilical artery pH values.
Bergus, GR; Goldsborough, K; Hartz, A; Levy, BT; Lofgren, M, 1999
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" However, when morphine and nalbuphine are mixed together, the clinical interactions in different combining ratios on analgesic effect and adverse events are unknown."( Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain.
Lin, CJ; Lin, FS; Lin, TF; Sun, WZ; Wang, YP; Yeh, YC, 2008
)
0.84
" Patient-controlled analgesia (PCA) requirement, postoperative pain, and adverse events were evaluated throughout the postoperative 24 h period."( Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain.
Lin, CJ; Lin, FS; Lin, TF; Sun, WZ; Wang, YP; Yeh, YC, 2008
)
0.55
" Numerical rating score, PCA requirement, nausea, vomiting, use of antiemetics, pruritus, use of antipruritics, and opioid-related adverse events were investigated at 1, 2, 4, and 24 hours postoperatively."( Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects.
Chan, WS; Chang, HC; Lin, CJ; Lin, TF; Sun, WZ; Wang, YP; Yeh, YC, 2009
)
0.66
" A causality assessment of the adverse reaction identified the antibiotic as the most probable cause of the observation."( A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012
)
0.38
"Although morphine is the standard opioid analgesic for pain control and has been widely used, certain drug-induced adverse effects have been reported as intolerable and need to be addressed."( A comparision of nalbuphine with morphine for analgesic effects and safety : meta-analysis of randomized controlled trials.
Chen, Y; Guo, T; Lu, J; Shu, C; Wu, QP; Yao, SL; Yin, P; Zeng, Z, 2015
)
0.76
"The present study shows that ERCP technique is safe under conscious sedation as it delivers balanced tranquillity."( Safety of Conscious Sedation in Patients Undergoing Endoscopic Retrograde Cholangio Pancreatography.
Anwar, A; Kamani, L; Memon, AL, 2018
)
0.48
" Adverse events occurred predominantly during dose titration and were of mild-to-moderate severity."( Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
Bernhard, JD; Hait, H; Legat, FJ; Nattkemper, L; Reich, A; Sadoghi, B; Sciascia, TR; Ständer, S; Szepietowski, JC; Weisshaar, E; Yosipovitch, G; Zeidler, C, 2022
)
1.02
" The primary endpoints are the effective rate of analgesia and the incidence of adverse reactions (nausea and vomiting, dizziness, itching, constipation, hypoxemia, and urinary retention); the secondary endpoints are pain intensity, satisfaction with analgesia, duration of surgery, postoperative hospital stay, average daily dose, uninterrupted completion rate of surgery without complaints of pain, quality of life assessment, and vital signs."( Analgesic efficacy and safety of nalbuphine versus morphine for perioperative tumor ablation: a randomized, controlled, multicenter trial.
Cheng, B; Huang, Z; Sun, J; Tang, Y; Wang, X; Xue, Y; Zhu, H, 2022
)
1
" The secondary endpoints were incidence CPSP at 3 months and adverse reactions up to 7 days after surgery."( Efficacy and safety of an extended-release sebacoyl dinalbuphine ester for laparoscopic cholecystectomy: A randomized controlled trial.
Chen, CY; Chen, JH; Chen, JL; Fu, CY; Lam, CF; Lee, YE; Lu, CY; Shiue, YL, 2023
)
1.16
" Significantly higher incidence of drug-related adverse events, including dizziness, nausea and injection site reactions, were recorded in the SDE group."( Efficacy and safety of an extended-release sebacoyl dinalbuphine ester for laparoscopic cholecystectomy: A randomized controlled trial.
Chen, CY; Chen, JH; Chen, JL; Fu, CY; Lam, CF; Lee, YE; Lu, CY; Shiue, YL, 2023
)
1.16
" Intramuscular injection of 150 mg SDE in patients with average body mass causes adverse events that could have been overlooked."( Efficacy and safety of an extended-release sebacoyl dinalbuphine ester for laparoscopic cholecystectomy: A randomized controlled trial.
Chen, CY; Chen, JH; Chen, JL; Fu, CY; Lam, CF; Lee, YE; Lu, CY; Shiue, YL, 2023
)
1.16
" Drug-related adverse events were mild-to-moderate and resolved by the treatment end."( Safety and Efficacy of Oral Nalbuphine on Postoperative Pain in Hemorrhoidectomy Patients: A Randomized, Double-blind, Placebo-controlled, Pivotal Trial.
Chen, WS; Hsiao, KH; Hu, OY; Jao, SW; Jiang, JK; Lee, CC; Lee, TY; Lin, CC; Lin, HC; Lin, TC; Wu, CC, 2023
)
1.2

Pharmacokinetics

Nalbuphine followed a linear three-compartment model with two distribution phases. The method is rapid, sensitive, selective and directly applicable to human pharmacokinetic studies involving nal Buphine.

ExcerptReferenceRelevance
" The half-life time in plasma was slightly shorter than in other studies, while the peak plasma concentrations were comparable with other results in the literature."( [Cumulative pharmacokinetics and clinical effects of nalbuphine in patients in the postoperative phase. An open multicenter study].
, 1989
)
0.53
" Elimination half-life (t1/2) was significantly shorter in group I (0."( Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.
Bergnieres, J; Blondel, Y; Gardin, ME; Grippat, JC; Jaillon, P; Lecocq, B; Meignan, S; Richard, MO; Vergnoux, O, 1989
)
0.6
" After administration, serum concentrations of nalbuphine were measured for 12 h using a high pressure liquid chromatography assay, and pharmacokinetic parameters were derived using a three compartment model."( The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.
Achola, KJ; Aitkenhead, AR; Lin, ES, 1988
)
0.79
" Mean Cmax values after 20 mg doses were 60 and 56 ng/ml."( The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.
Lee, FH; Lo, MW; Schary, WL; Whitney, CC, 1987
)
0.51
"For the purpose of selecting an animal model for the study of the aging effect on the pharmacokinetics of nalbuphine, the pharmacokinetic properties in young and in aged rabbits were reported."( The effect of aging on the pharmacokinetics of nalbuphine in rabbits.
Ho, ST; Hu, OY; Hu, TM; Wang, JJ, 1995
)
0.76
" Pharmacokinetic application in three surgical patients and four rabbits revealed that nalbuphine followed a linear three-compartment model with two distribution phases."( Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies.
Chiang, PS; Ho, ST; Hu, OY; Lee, SC; Wang, JJ, 1996
)
0.86
" The ease of the proposed method of analysis, as well as its high accuracy and sensitivity allow its application to pharmacokinetic studies."( Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route.
Bessard, G; Guimier, C; Nicolle, E; Veitl, S, 1997
)
0.63
" This method has been used to determine the pharmacokinetic parameters of nalbuphine in children."( Determination of nalbuphine in human plasma by high-performance liquid chromatography with electrochemical detection. Application to a pharmacokinetic study.
Audran, M; Bressolle, F; de Cazanove, F; Kinowski, JM; Rochette, A, 1997
)
0.87
" The method was applied successfully to a pharmacokinetic study of SDN administered at 20 mg/kg to two beagle dogs."( High-performance liquid chromatographic method for the simultaneous determination of nalbuphine and its prodrug, sebacoyl dinalbuphine ester, in dog plasma and application to pharmacokinetic studies in dogs.
Ho, ST; Hsiong, CH; Hu, OY; Pao, LH, 2000
)
0.53
"The objective of this work was to study the in vitro characteristics as well as in vivo pharmacokinetic performance of a series nalbuphine (NA) prodrug-loaded microspheres."( Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies.
Hu, OY; Kuo, JH; Liu, FI; Sung, KC, 2003
)
0.79
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The aim of this study was to characterize the population pharmacokinetics of nalbuphine in patients with ages ranging from 1 to 11 yr and to identify patient characteristics partially explaining inter-individual variability in nalbuphine pharmacokinetic parameters."( Population pharmacokinetics of nalbuphine after surgery in children.
Bressolle, F; Capdevila, X; Dadure, C; Khier, S; Kinowski, JM; Rochette, A, 2011
)
0.88
" In the children of this study, total clearance expressed in litre h(-1) kg(-1) decreased significantly with increasing age and the elimination half-life significantly increased."( Population pharmacokinetics of nalbuphine after surgery in children.
Bressolle, F; Capdevila, X; Dadure, C; Khier, S; Kinowski, JM; Rochette, A, 2011
)
0.66
" The method is rapid, sensitive, selective and directly applicable to human pharmacokinetic studies involving nalbuphine."( Validated LC-MS/MS assay for the quantitative determination of nalbuphine in human plasma and its application to a pharmacokinetic study.
Cai, LJ; Peng, WX; Wang, XM; Yang, J; Zhang, J; Zhang, QZ; Zhu, RH, 2011
)
0.82
" Pharmacokinetic parameters were estimated by use of computer software."( Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Keller, DL; Klauer, JM; KuKanich, B; Paul-Murphy, JR; Rodríguez-Ramos Fernández, J; Sanchez-Migallon Guzman, D, 2011
)
0.69
" Pharmacokinetic parameters were estimated with computer software."( Pharmacokinetics of long-acting nalbuphine decanoate after intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Brown, CS; Heath, TD; Krugner-Higby, LA; KuKanich, B; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2013
)
0.67
" The mean terminal half-life was 20."( Pharmacokinetics of long-acting nalbuphine decanoate after intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Brown, CS; Heath, TD; Krugner-Higby, LA; KuKanich, B; Paul-Murphy, JR; Sanchez-Migallon Guzman, D, 2013
)
0.67
" The method is sensitive, selective and directly applicable to human pharmacokinetic studies involving nalbuphine."( Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in humans.
Ho, ST; Hsiong, CH; Hu, OY; Huang, PW; Liu, HT; Lu, CC; Pao, LH, 2013
)
0.89
" Mean half-life was 14."( Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
Alcorn, H; Berg, J; Hait, H; Hawi, A; Hines, C; Sciascia, T, 2015
)
0.74
" Here we compared the pharmacokinetic profiles of 10 mg/kg nalbuphine in male C57BL/6 mice subcutaneous or intraperitoneal administration."( Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.
Kick, BL; Shu, P; Sun, D; Taylor, DK; Wen, B, 2017
)
0.99
" We developed and validated a rapid, simple and sensitive method by ultra-performance liquid chromatography-tandem mass spectrometry (MS/MS) for the simultaneous quantitation of nalbuphine in human plasma, and we reported the pharmacokinetic features of patients during general anesthesia for abdominal surgery."( A Validated UHPLC-MS/MS Method for Determination of Nalbuphine in Human Plasma and Application for Pharmacokinetic Study of Patients Undergoing General Anesthesia.
Feng, Z; Gao, J; Gao, X; Heng, T; Hua, L; Jia, L; Nie, X; Sun, Y; Wang, M; Zhang, Y, 2023
)
1.35
"Population pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) models were used to describe the exposure-response (E-R) relationship between nalbuphine exposure and two widely used rating scales for itch: the Numerical Rating Scale for the subject's 'average'; itch experience (NRS-AV) and the Worst Itch (WI-NRS), with 24-h recall."( A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
Eudy-Byrne, R; Hawi, A; Riggs, M; Rohatagi, S; Sciascia, T, 2023
)
1.34
" The measured pharmacodynamic variables were sedative and analgesic effects and the effect on ataxia and some physiological parameters."( Pharmacodynamics and pharmacokinetics of nalbuphine in xylazine‑sedated horses.
Gadallah, S; Hammad, A; Misk, T; Mourad, A; Sharshar, A; Thabet, N, 2022
)
0.99

Compound-Compound Interactions

This study compared the effectiveness of epidural nalbuphine and sufentanil in combination with ropivacaine for labor analgesia. The analgesic effect of subarachnoid administration of tetracaine combined with low dose morphine or nal Buphine for spinal anesthesia was evaluated in 60 ASA physical status class I or II patients.

ExcerptReferenceRelevance
"The analgesic effect of subarachnoid administration of tetracaine combined with low dose morphine or nalbuphine for spinal anesthesia was evaluated in 60 ASA physical status class I or II patients."( [The analgesic effect of subarachnoid administration of tetracaine combined with low dose morphine or nalbuphine for spinal anesthesia].
Lin, ML, 1992
)
0.71
"This study compared the analgesic efficacy, sedative, and amnesic properties, and side effects of nalbuphine versus meperidine as intravenous premedicants in combination with intravenous diazepam for the treatment of outpatients undergoing the removal of impacted third molars with alveolar nerve block anesthesia."( A double-blind comparison of nalbuphine and meperidine hydrochloride as intravenous analgesics in combination with diazepam for oral surgery outpatients.
Scott, RF, 1987
)
0.78
" These results are similar to previous results obtained with tripelennamine and pentazocine suggesting that nalbuphine may have abuse potential if combined with tripelennamine."( Effects of nalbuphine alone and in combination with tripelennamine on rewarding brain stimulation thresholds in the rat.
Kornetsky, C; Unterwald, EM, 1986
)
0.87
" Studies revealed that tripelennamine (Tp) alone produced antinociception (ANTI) in mice and also caused potentiation when combined with morphine (M) or nalbuphene (NB)."( The effect of tripelennamine alone and in combination with opiates to produce antinociception in mice.
Hanig, JP; Hui, FW; Sun, CJ; Tocus, EC, 1983
)
0.27
" The population was divided into two groups: group 1 received 20 mg of nalbuphine hydrochloride and group 2 received 2 g of propacetamol combined with 10 mg of nalbuphine hydrochloride."( [Comparison of the analgesic efficacy of nalbuphine and its combination with propacetamol during the immediate postoperative period in gynecologic-obstetric surgery].
Granry, JC; Jacob, JP; Monrigal, C, 1994
)
0.79
" The aim of this randomized double blind, dose-ranging study was to determine the minimum single effective dose of dexamethasone combined with ondansetron for the prevention of PONV in patients undergoing laparoscopic cholecystectomy."( Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
Atef, A; Elhakim, M; Mahmoud, K; Nafie, M, 2002
)
0.31
"Our results suggest that 8 mg is the minimum dose of dexamethasone that, combined with ondansetron 4 mg will effectively prevent PONV in patients undergoing laparoscopic cholecystectomy."( Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
Atef, A; Elhakim, M; Mahmoud, K; Nafie, M, 2002
)
0.31
"Each dog was treated four times: physiological saline (1 mL) combined with nalbuphine (0."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
0.98
"Butorphanol promoted a higher sedative effect than nalbuphine when alone and combined with acepromazine."( Comparison of the sedative effects of nalbuphine and butorphanol, alone or in combination with acepromazine in dogs.
Coelho, CM; Gomes, VH; Marques, JL; Oliveira, RL; Silva, MF, 2018
)
1
"The goal of this study was to determine whether a drug combination using nalbuphine with dexmedetomidine and tiletamine/zolazepam is non-inferior to one that uses butorphanol."( Use of nalbuphine as a substitute for butorphanol in combination with dexmedetomidine and tiletamine/zolazepam: a randomized non-inferiority trial.
Cornell, HN; Hofmeister, EH; Kelsey, SE; Kreisler, RE; Smith, VA, 2020
)
1.24
" The present study was conducted to explore an ideal concentration of nalbuphine for post-CS intravenous analgesia by evaluating the analgesic effects and side-effects of three different concentrations of nalbuphine combined with hydromorphone for post-CS intravenous analgesia in healthy parturients."( A comparative study of three concentrations of intravenous nalbuphine combined with hydromorphone for post-cesarean delivery analgesia.
Chen, XZ; Huang, CY; Li, SX; Xu, LL; Yang, MJ, 2020
)
1.04
"To compare the propofol infusion rate and cardiopulmonary effects during total intravenous anesthesia with propofol alone and propofol combined with methadone, fentanyl or nalbuphine in domestic chickens undergoing ulna osteotomy."( Total intravenous anesthesia in domestic chicken (Gallus gallus domesticus) with propofol alone or in combination with methadone, nalbuphine or fentanyl for ulna osteotomy.
Alievi, MM; Boos, MZ; Gutierrez, LG; Herrera, JR; Mombach, VS; Monteiro, ER; Santos, EA, 2020
)
0.96
" This study compared the effectiveness of epidural nalbuphine and sufentanil in combination with ropivacaine for labor analgesia, respectively."( The Effect of Epidural Nalbuphine Combined With Ropivacaine on Epidural Analgesia During Labor: A Multicenter, Randomized, Double-blind, Controlled Study.
Cao, R; Chen, Z; Huang, S; Sun, X; Tang, S; Zhou, M; Zhou, Q, 2021
)
1.18
"BACKGROUND The goal of this study was to investigate different doses of nalbuphine combined with dexmedetomidine in the postoperative treatment of laparoscopic oophorocystectomy."( Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy.
Hu, X; Liu, X; Song, J; Zhang, Y, 2021
)
1.18
" Therefore, this study concluded that Nabufine combined with SAPB can make the vital signs of intraoperative patients more stable, which is worthy of clinical promotion."( Effects of Nalbuphine Combined with Anterior Serratus Plane Block in Elderly Patients Undergoing Thoracoscopic Surgery.
Li, H; Li, Y; Liu, Y; Wu, C, 2022
)
1.11
"To compare sedative, cardiopulmonary, and adverse effects of 3 nalbuphine doses, administered alone or in combination with acepromazine, in dogs."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
1.22
"0 mg/kg, intravenously [IV]) combined with physiologic saline solution (1 mL, IV; treatments SN1."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
0.98
"All nalbuphine doses promoted mild sedation when administered alone, and moderate sedation when combined with acepromazine."( Comparison of the sedative effects of three nalbuphine doses, alone or combined with acepromazine, in dogs.
da Silva, MFA; de Cerqueira Teixeira, JG; Gomes, VH; Janiques Borré, LDS; Marques, JLR, 2022
)
1.54
"This retrospective study evaluated the efficacy, opioid consumption, and safety profile of two patient-controlled intravenous analgesia (PCIA) regimens (sufentanil combined with nalbuphine vs sufentanil alone) after cesarean section (CS)."( Sufentanil Combined with Nalbuphine via Patient-Controlled Intravenous Analgesia After Cesarean Section: A Retrospective Evaluation.
Ma, Y; Mu, X; Nie, H; Wang, H; Wang, L; Wang, Y; Zhang, Z; Zheng, Z, 2022
)
1.22
"Parturients (n = 1808) received sufentanil combined with nalbuphine (SN group) or sufentanil alone (S group) as PCIA after CS."( Sufentanil Combined with Nalbuphine via Patient-Controlled Intravenous Analgesia After Cesarean Section: A Retrospective Evaluation.
Ma, Y; Mu, X; Nie, H; Wang, H; Wang, L; Wang, Y; Zhang, Z; Zheng, Z, 2022
)
1.27
"Compared with sufentanil alone, sufentanil combined with nalbuphine for PCIA provided superior analgesia in parturient women after CS."( Sufentanil Combined with Nalbuphine via Patient-Controlled Intravenous Analgesia After Cesarean Section: A Retrospective Evaluation.
Ma, Y; Mu, X; Nie, H; Wang, H; Wang, L; Wang, Y; Zhang, Z; Zheng, Z, 2022
)
1.27
" This study investigated the effect of different doses of nalbuphine combined with sufentanil for postoperative analgesia in patients undergoing a second cesarean section."( Nalbuphine 20 mg combined with sufentanil 2 μg/kg exerts a better postoperative analgesia effect in patients undergoing a second cesarean section: a randomised trial.
Bo, Y; Chen, D; Huang, Y; Jin, H; Li, X; Lin, L; Liu, J; Pan, W; Peng, J; Zhao, Y, 2022
)
2.41
"A single intravenous injection of nalbuphine 20 mg 10 minutes before the infusion of oxytocin combined with sufentanil 2 µg/kg could be safely used for postoperative analgesia in patients undergoing a second cesarean section and could effectively inhibit uterine contractions induced by oxytocin and reduce adverse reactions."( Nalbuphine 20 mg combined with sufentanil 2 μg/kg exerts a better postoperative analgesia effect in patients undergoing a second cesarean section: a randomised trial.
Bo, Y; Chen, D; Huang, Y; Jin, H; Li, X; Lin, L; Liu, J; Pan, W; Peng, J; Zhao, Y, 2022
)
2.44

Bioavailability

In both species nalbuphine had high systemic clearance and low oral bioavailability as a result of extensive first-pass metabolism. The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses.

ExcerptReferenceRelevance
" Absolute bioavailability of nalbuphine increased from F = 12% in group II to 46."( Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.
Bergnieres, J; Blondel, Y; Gardin, ME; Grippat, JC; Jaillon, P; Lecocq, B; Meignan, S; Richard, MO; Vergnoux, O, 1989
)
0.89
" The disposition of (-)17-(cyclobutylmethyl)-4,5 alpha-epoxymorphinan-3,6 alpha, 14-triol (Nalbuphine, Nubain) and its 3-acetylsalicylate ester has been studied in rat and dog to determine whether this analogue can improve the oral bioavailability of nalbuphine."( Species variation in the disposition of nalbuphine and its acetylsalicylate ester analogue.
Harrelson, JC; Wong, YJ, 1988
)
0.76
" Bioavailability of the oral preparation was 11."( The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.
Achola, KJ; Aitkenhead, AR; Lin, ES, 1988
)
0.53
" Absolute bioavailability of the orally administered forms of nalbuphine ranged from 16."( The disposition and bioavailability of intravenous and oral nalbuphine in healthy volunteers.
Lo, MW; Schary, WL; Whitney, CC, 1987
)
0.76
" The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine."( The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.
Lee, FH; Lo, MW; Schary, WL; Whitney, CC, 1987
)
0.7
" Gastric emptying in the immediate postoperative period was also assessed in each patient by measuring the rate of absorption of orally administered paracetamol."( Analgesic and gastrointestinal effects of nalbuphine--a comparison with pethidine.
Couch, RA; Mark, A; Slattery, PJ, 1986
)
0.54
" In both species nalbuphine had high systemic clearance and low oral bioavailability as a result of extensive first-pass metabolism."( Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs.
Aungst, BJ; Lam, G; Shefter, E,
)
0.82
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The in vivo pharmacokinetic studies after subcutaneous injection of NAP-loaded microsphere showed a sustained plasma nalbuphine (NA)-time profile, with 100% relative bioavailability comparing to the AUC obtained after intravenous injection."( Controlled release of nalbuphine propionate from biodegradable microspheres: in vitro and in vivo studies.
Sung, KC; Wang, JJ; Yen, SY; Yoa-Pu Hu, O, 2001
)
0.83
"0% relative bioavailability for microspheres loaded with nalbuphine propionate (NAP), nalbuphine pivalate (NPI), and nalbuphine decanoate (NDE), respectively."( Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies.
Hu, OY; Kuo, JH; Liu, FI; Sung, KC, 2003
)
0.83
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"In Hispaniolan Amazon parrots, nalbuphine appeared to have good bioavailability after IM administration and was rapidly cleared after IV and IM administration."( Pharmacokinetics of nalbuphine hydrochloride after intravenous and intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).
Barker, SA; Keller, DL; Klauer, JM; KuKanich, B; Paul-Murphy, JR; Rodríguez-Ramos Fernández, J; Sanchez-Migallon Guzman, D, 2011
)
0.98
"Tween-PEG successfully improved oral NAL bioavailability and could formulate a useful oral dosage form for patient's convenience."( Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.
Ho, ST; Hsiong, CH; Hu, OY; Huang, PW; Lin, MJ; Shih, TY; Wang, HJ, 2014
)
0.63
" The bioavailability of nalbuphine from intramuscularly injected DNS relative to that from nalbuphine HCl was 85."( Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended-release formulation.
Chern, WH; Huang, JD; Huang, WC; Kuo, HY; Tai, L; Tien, YE; Uang, YS, 2017
)
1.08
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Nalbuphine (group 3) allows a reduction in the mean dosage of midazolam required to produce satisfactory sedation and effected a more rapid recovery time compared to group 12 and 2. With increasing dosage of nal Buphine there appeared to be a limit to the extent of respiratory depression.

ExcerptRelevanceReference
"To determine whether nalbuphine might replace fentanyl as the principal opioid for anesthesia during coronary artery bypass surgery, 20 patients undergoing myocardial revascularization were anesthetized with flunitrazepam and with a continuous infusion of either nalbuphine (an opioid agonist-antagonist) or fentanyl (a pure opioid agonist) in equipotent dosage ratio of 333:1."( Comparison of nalbuphine and fentanyl anesthesia for coronary artery bypass surgery. Hemodynamics, hormonal response, and postoperative respiratory depression.
Gattiker, RI; Schmid, ER; Weiss, BM, 1991
)
0.96
" No dose-response effect was apparent in the nalbuphine dose-range studied."( A dose-response study of nalbuphine for post-thoracotomy epidural analgesia.
Baxter, AD; Hull, K; Langanière, S; McGilveray, IJ; Samson, B, 1991
)
0.84
" Nalbuphine was not consistently identified as either pentazocine or hydromorphone and produced relatively flat dose-response functions on most of the subjective effect measures."( Drug discrimination in human postaddicts: agonist-antagonist opioids.
Bickel, WK; Bigelow, GE; Liebson, IA; Preston, KL, 1989
)
1.19
"Pharmacokinetic data and analgetic potency of nalbuphine hydrochloride (Nubain) under conditions of postoperative respiratory treatment and repeated dosage was investigated in a multicenter study."( [Cumulative pharmacokinetics and clinical effects of nalbuphine in patients in the postoperative phase. An open multicenter study].
, 1989
)
0.78
" The low- and high-dose nalbuphine groups clinically resembled the fentanyl group in terms of dosing frequency and patients' self-ratings of postoperative analgesia."( A comparison of clinical and psychological effects of fentanyl and nalbuphine in ambulatory gynecologic patients.
Earls, F; Garfield, FB; Garfield, JM; Philip, BK; Roaf, E, 1987
)
0.82
" Despite high dosage in some cases (up to 200 mg in an hour) no clinically important cardiovascular or respiratory effects were observed."( On-demand nalbuphine for post-operative pain relief.
Kay, B; Krishnan, A, 1986
)
0.67
"Systemic administration of beta-funaltrexamine (beta-FNA) 24 hr before analgesic testing produced approximately a 10-fold parallel shift in the dose-response curves of the prototypic mu agonists morphine, I-methadone, fentanyl and etorphine in the mouse abdominal constriction test."( Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Hynes, MD; Leander, JD; Reel, JK; Zimmerman, DM, 1987
)
0.27
"5 mg/kg) allowed for a significant reduction in the mean dosage of midazolam required to produce satisfactory sedation when compared with trials where midazolam was used alone."( New intravenous sedative combinations in oral surgery: a comparative study of nalbuphine or pentazocine with midazolam.
Hook, PC; Lavery, KM, 1988
)
0.5
" Blood specimens were obtained up to 15 h after dosing for determination of nalbuphine."( The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.
Lee, FH; Lo, MW; Schary, WL; Whitney, CC, 1987
)
0.74
" With increasing dosage of nalbuphine there appeared to be a limit to the extent of respiratory depression."( Respiratory function following nalbuphine and morphine in anaesthetized man.
Klepper, ID; Mapleson, WW; Rosen, M; Vickers, MD, 1986
)
0.85
" This increase was reversed after the test dosage was doubled from 20 mg to 40 mg nalbuphine."( [Hemodynamic effects of nalbuphine in patients with acute respiratory insufficiency].
Knoch, M; Konder, H; Lennartz, H; von Rechenberg, H, 1986
)
0.8
", oral, and rectal dosing was evaluated in rats and dogs."( Oral and rectal nalbuphine bioavailability: first-pass metabolism in rats and dogs.
Aungst, BJ; Lam, G; Shefter, E,
)
0.48
" Dose-response curves were constructed using the rat tail pressure test for analgesia which indicated a rank order of potency of buprenorphine much greater than morphine greater than butorphanol greater than xorphanol = nalbuphine."( Physical dependence induced by opiate partial agonists in the rat.
Howlett, GJ; McCarthy, PS, 1984
)
0.45
" The increasing morphine dosage was associated with progressive rightward displacements and ultimately decreases in the slope of the CO2 response curves."( Analgesic and respiratory depressant activity of nalbuphine: a comparison with morphine.
DiFazio, CA; Gal, TJ; Moscicki, J, 1982
)
0.52
" At 1 mg/kg, CCAM caused a 300-fold shift of the alfentanil dose-response curve and also depressed the maximum response rates."( Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
Lewis, JW; Woods, JH; Zernig, G, 1997
)
0.3
" Naloxone (1 microM) or norbinaltorphimine (10 nM) shifted the dose-response curve of (-)-U50,488H to the right by 100-fold."( Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Chen, C; Li, JG; Liu-Chen, LY; Luo, LY; Zhu, J, 1997
)
0.3
" Slopes for dose-response curves were determined."( Effects of nalbuphine, pentazocine and U50488H on gastric emptying and gastrointestinal transit in the rat.
Asai, T; Mapleson, WW; Power, I, 1998
)
0.69
"To search for the optimal dosage of nalbuphine relief of intrathecal-morphine induced pruritus after caesarean section."( Optimal dose of nalbuphine for treatment of intrathecal-morphine induced pruritus after caesarean section.
Ketchada, U; Oranuch, K; Siriprapa, S; Somrat, C; Thipawan, R, 1999
)
0.92
" Dose-response and time-course determinations were performed with various opioids."( Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor.
Barrett, AC; Bowman, JR; Cook, CD; Picker, MJ; Roach, EL, 2000
)
0.31
" Self-administration of cocaine was readily initiated according to an inverted U-shaped unit dose-response curve."( Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice.
Gerrits, MA; Kuzmin, AV; van Ree, JM; Zvartau, EE, 2000
)
0.57
" Clocinnamox (10 mg/kg) produced a 7- and 12-fold further decrease in morphine and fentanyl potency, respectively, a reduction in the slope of the morphine dose-response curve, and a suppression of the maximal morphine responding for buprenorphine."( Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
Walker, EA; Young, AM, 2002
)
0.31
" In Study 2, we evaluated the antinociceptive effects of IM nalbuphine base and esters with a dosage of 25 micro mol/kg."( The antinociceptive effect of nalbuphine and its long-acting esters in rats.
Chen, YW; Chu, KS; Ho, ST; Wang, JJ; Yoa-Pu Hu, O, 2003
)
0.85
" The aim of this study was to evaluate the antinociceptive effect and duration of action of an oily dosage form of nalbuphine base and to see whether its effect could last longer compared with nalbuphine HCl."( The antinociceptive effect of a long-acting nalbuphine preparation in rabbits.
Chen, YW; Ho, ST; Hu, OY; Liu, KS; Tzeng, JI; Wang, JJ, 2003
)
0.79
"This study aimed to determine which of two paramedic administered nalbuphine dosing regimens combined the greater analgesic effect with the minimum of adverse events."( Less IS less: a randomised controlled trial comparing cautious and rapid nalbuphine dosing regimens.
Hinton, C; Jones, T; Smith, K; Thomas, G; Whitfield, R; Woollard, M, 2004
)
0.79
"Patients suffering from chest pain or trauma were randomised to receive either a rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three) or a cautious regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg)."( Less IS less: a randomised controlled trial comparing cautious and rapid nalbuphine dosing regimens.
Hinton, C; Jones, T; Smith, K; Thomas, G; Whitfield, R; Woollard, M, 2004
)
0.56
"A rapid dosing regimen of nalbuphine using 10 mg increments is more effective than and equally as safe as a cautious regimen using 5 mg increments."( Less IS less: a randomised controlled trial comparing cautious and rapid nalbuphine dosing regimens.
Hinton, C; Jones, T; Smith, K; Thomas, G; Whitfield, R; Woollard, M, 2004
)
0.86
" Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration."( In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine.
Ho, ST; Hsiong, CH; Hu, OY; Pao, LH; Wang, JJ, 2005
)
0.55
"We describe the first studies of a simple and sensitive spectrofluorimetric and spectrophotometric methods for the analysis of nalbuphine (NLB) in dosage form and biological fluids."( New spectrofluorimetric and spectrophotometric methods for the determination of the analgesic drug, nalbuphine in pharmaceutical and biological fluids.
Ali, II; El-Didamony, AM,
)
0.55
" Further studies with other types of nociceptive stimulation, dosages, and dosing intervals as well as clinical trials are needed to fully evaluate the analgesic effects of nalbuphine decanoate in psittacine birds."( Antinociceptive effects of long-acting nalbuphine decanoate after intramuscular administration to Hispaniolan Amazon parrots (Amazona ventralis).
Braun, JM; Brown, CS; Heath, TD; Keuler, NS; Krugner-Higby, LA; Paul-Murphy, JR; Sanchez-Migallon Guzman, D; Steagall, PV, 2013
)
0.85
"Tween-PEG successfully improved oral NAL bioavailability and could formulate a useful oral dosage form for patient's convenience."( Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans.
Ho, ST; Hsiong, CH; Hu, OY; Huang, PW; Lin, MJ; Shih, TY; Wang, HJ, 2014
)
0.63
" Increased dosing might result in a ceiling effect, and thus less analgesia than expected."( Nalbuphine for postoperative pain treatment in children.
Pogatzki-Zahn, E; Reichl, SU; Schnabel, A; Zahn, PK, 2014
)
1.85
" This compound has received little attention as an analgesic for mice, and standard dosage regimens have not been developed."( Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.
Kick, BL; Shu, P; Sun, D; Taylor, DK; Wen, B, 2017
)
0.75
" There are advantages and disadvantages in using these 2 opioids which are discussed, and potential dosing strategies are outlined."( What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl.
Behm, B; Davis, MP; Fernandez, C; McPherson, ML; Mehta, Z, 2018
)
0.48
" The dosage of 10 mg improves the quality of the anesthesia with less incidence of side effects."( Efficacy of Nalbuphine as an Adjuvant to Ropivacaine in Ultrasound-guided Supraclavicular Brachial Block: A Prospective Randomized Controlled Study.
Kalika, P; Ran, R; Xiao, Y; Xue, R; Zhen, M; Zheng, J, 2020
)
0.94
" The NLB-SLNs was screened for cytotoxicity in human embryonic kidney cells (HEK-293), and the dosage was considered safe when administered intranasally in animal since no detectable effect to the brain was observed."( Intranasal solid lipid nanoparticles for management of pain: A full factorial design approach, characterization & Gamma Scintigraphy.
Bhatnagar, A; Hasan, N; Jain, GK; Karwasra, R; Khan, N; Khanna, K; Khanna, S; Kumar, A; Nishad, DK; Popli, H; Rawat, S; Sharma, N, 2021
)
0.62
"Subjects with moderate-to-severe PN were randomized to NAL-ER 81 mg (NAL-ER81) or 162 mg (NAL-ER162) tablets twice-daily or placebo for 8 weeks of stable dosing following a 2-week titration period."( Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
Bernhard, JD; Hait, H; Legat, FJ; Nattkemper, L; Reich, A; Sadoghi, B; Sciascia, TR; Ständer, S; Szepietowski, JC; Weisshaar, E; Yosipovitch, G; Zeidler, C, 2022
)
1.02
"The aim of this study is to assess the current situation in out of hospital pain management in Germany regarding the substances, indications, dosage and the delegation of the use of analgesics to emergency medical service (EMS) staff."( Application of analgesics in emergency services in Germany: a survey of the medical directors.
Scharonow, M; Scharonow, O; Vilcane, S; Weilbach, C, 2023
)
0.91
" The cumulative dosage of diclofenac in the PHN131 group was only around half of that in the placebo group ( P <0."( Safety and Efficacy of Oral Nalbuphine on Postoperative Pain in Hemorrhoidectomy Patients: A Randomized, Double-blind, Placebo-controlled, Pivotal Trial.
Chen, WS; Hsiao, KH; Hu, OY; Jao, SW; Jiang, JK; Lee, CC; Lee, TY; Lin, CC; Lin, HC; Lin, TC; Wu, CC, 2023
)
1.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mu-opioid receptor antagonistAny compound that exhibits antagonist activity at the mu-opioid receptor
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic heteropentacyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Nalbuphine Action Pathway3211

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency27.83810.000221.22318,912.5098AID743035; AID743040; AID743063
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency31.62280.01237.983543.2770AID1346984
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.58150.000229.305416,493.5996AID743069; AID743078; AID743079; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency25.11890.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)100.00000.17004.559010.0000AID1594139
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)0.05780.00010.813310.0000AID152239; AID286314; AID417162; AID625163
Mu-type opioid receptorHomo sapiens (human)Ki0.00410.00000.419710.0000AID286302; AID416813; AID625163
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)1.11950.00020.75218.0140AID148078; AID625161
Delta-type opioid receptorHomo sapiens (human)Ki0.49500.00000.59789.9300AID286304; AID416814; AID625161
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)0.09700.00001.201110.0000AID147859; AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki0.01640.00000.362410.0000AID286303; AID416815; AID625162
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)100.00000.17004.559010.0000AID1594139
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)100.00000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1594140; AID1594141
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)0.03000.00000.32639.4000AID286312; AID417156
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)0.09950.00000.22448.9900AID286308; AID417160; AID640395; AID640424
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (92)

Processvia Protein(s)Taxonomy
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1607774Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as duration above 50% maximum possible analgesia at 1 mg/kg administered as intra-cisternal injection by Randall-Selitto test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID640425Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID416816Selectivity ratio of IC50 for human delta opioid receptor to IC50 for human mu opioid receptor2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1607777Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as duration above 50% maximum possible analgesia at 1 mg/kg administered as intra-cisternal injection measured over 2.5 hrs by cold-ethanol tail-flick test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1607776Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as reduction in tail-flick response by measuring AUC (0 to t) of tail flick test at 1 mg/kg administered as intra-cisternal injection measured over 2.5 hrs by col2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID286312Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID640423Agonist activity at human KOPR expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by liquid scintillation counting relative to U50,488H2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID417157Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to basal level2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID417156Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID152239Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID640430Ratio of EC50 for agonist activity at human KOPR expressed in U2OS cells assessed as beta-arrestin2 recruitment to EC50 for agonist activity at human KOPR expressed in CHO cells assessed as [35S]GTPgammaS binding2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID417161Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to basal level2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID417165Antagonist activity against human kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-stimulated [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1607782Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as reduction in tail-flick response by measuring AUC (0 to t) of tail flick test at 50 mg/kg, ip measured over 2.5 hrs by cold-ethanol tail-flick test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID286305Ratio of Ki for human opioid kappa receptor to Ki for human opioid gamma receptor2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID417162Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID286310Antagonist activity at human opioid kappa receptor expressed in CHO cells assessed as inhibition of U-50488-stimulated [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID640394Agonist activity at human KOPR expressed in U2OS cells assessed as beta-arrestin2 recruitment after 90 mins by DiscoveRx PathHunter assay relative to salvA2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID286302Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID640395Agonist activity at human KOPR expressed in U2OS cells assessed as beta-arrestin2 recruitment after 90 mins by DiscoveRx PathHunter assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID286304Displacement of [3H]naltrindole from human opioid delta receptor expressed in CHO cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1607780Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as duration above 50% maximum possible analgesia at 50 mg/kg, ip by Randall-Selitto test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID640424Agonist activity at human KOPR expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by liquid scintillation counting2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID286314Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as inhibition of DAGO-stimulated [35S]GTPgammaS binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID416815Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID640426Displacement of [3H]diprenorphine from rat MOPR expressed in CHO cells2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID417160Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID147859Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID286311Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID286313Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as maximal inhibition of DAGO-stimulated [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID1607773Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as reduction in paw pressure by measuring AUC (0 to t) of paw pressure test at 1 mg/kg administered as intra-cisternal injection by Randall-Selitto test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID640431Partial agonist activity at KOPR expressed in human U2OS cells co-expressing GFP-tagged beta-arrestin2 assessed as translocation of GFP-tagged beta-arrestin2 at 10 uM incubated 120 mins in serum deprived medium prior drug addition measured after 10 mins b2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1607778Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as maximum possible analgesia at 1 mg/kg administered as intra-cisternal injection measured over 2.5 hrs by cold-ethanol tail-flick test relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID416817Selectivity ratio of IC50 for human kappa opioid receptor to IC50 for human mu opioid receptor2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID286303Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1607784Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as maximum possible analgesia at 50 mg/kg, ip measured over 2.5 hrs by cold-ethanol tail-flick test relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID286306Ratio of Ki for human opioid kappa receptor to Ki for human opioid delta receptor2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID148078Binding affinity against delta-opiate receptor (human) using [3H]-DPDPE radioligand2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
AID1607775Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as maximum possible analgesia at 1 mg/kg administered as intra-cisternal injection by Randall-Selitto test relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID286307Agonist activity at human opioid kappa receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID286309Antagonist activity at human opioid kappa receptor expressed in CHO cells assessed as maximal inhibition of U-50488-stimulated [35S]GTP-gamma-S binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1607783Antinociceptive activity in Sprague-Dawley rat model of thermal-induced nociception assessed as duration above 50% maximum possible analgesia at 50 mg/kg, ip measured over 2.5 hrs by cold-ethanol tail-flick test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID416813Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID286308Agonist activity at human opioid kappa receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID416814Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO cells after 3 hrs by scintillation counting2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1607779Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as reduction in paw pressure by measuring AUC (0 to t) of paw pressure test at 50 mg/kg, ip by Randall-Selitto test2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID1607781Antinociceptive activity in Sprague-Dawley rat model of paw mechanical allodynia assessed as maximum possible analgesia at 50 mg/kg, ip by Randall-Selitto test relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: Synthesis and biological evaluation.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1346361Human delta receptor (Opioid receptors)2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID1346341Mouse kappa receptor (Opioid receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jul-15, Volume: 90, Issue:14
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.
AID1346329Human kappa receptor (Opioid receptors)1997The Journal of pharmacology and experimental therapeutics, Aug, Volume: 282, Issue:2
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
AID1346364Human mu receptor (Opioid receptors)2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (734)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990224 (30.52)18.7374
1990's186 (25.34)18.2507
2000's133 (18.12)29.6817
2010's103 (14.03)24.3611
2020's88 (11.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.36 (24.57)
Research Supply Index6.97 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index153.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials269 (33.92%)5.53%
Reviews44 (5.55%)6.00%
Case Studies40 (5.04%)4.05%
Observational6 (0.76%)0.25%
Other434 (54.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (80)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair: A Prospective, Randomized Comparative, Controlled Double-blind Study. [NCT06100315]60 participants (Anticipated)Observational2023-12-31Not yet recruiting
Effect of IV Nalbuphine on Postoperative Nausea and Vomiting Following Intrathecal Morphine in Patients Undergoing Inguinal Hernia Repair [NCT05704673]80 participants (Anticipated)Interventional2023-06-01Not yet recruiting
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study) [NCT03497975]Phase 2/Phase 3353 participants (Actual)Interventional2018-08-07Completed
Analgesic Efficacy of Erector Spinae Plane Block Versus Opioid Based General Anesthesia During Laparoscopic Bariatric Surgery; a Randomized Controlled Study [NCT03798522]28 participants (Actual)Interventional2019-02-01Completed
To Explore the Effects of Naldebain Combined With Thoracic Paravertebral Block in Video-assisted Thoracoscopic Surgery. [NCT04962152]Phase 460 participants (Anticipated)Interventional2021-07-07Recruiting
Prospective Comparative Study Between Ultrasound-guided Continuous Erector Spinae Plane Block and the Use of Intravenous Patient Controlled Analgesia for Management of Pain in Patients With Multiple Fracture Ribs [NCT05975294]60 participants (Anticipated)Interventional2023-08-31Not yet recruiting
A Randomized Controlled Trial to Compare the Efficacy and Safety of NALDEBAIN With Intravenous Patient-Controlled Analgesia With Fentanyl for the Treatment of Post-Laparotomy Surgery [NCT03296488]Phase 4110 participants (Anticipated)Interventional2017-08-17Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF) [NCT05964335]Phase 2160 participants (Anticipated)Interventional2023-10-01Not yet recruiting
A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management [NCT02468128]Phase 2/Phase 3221 participants (Actual)Interventional2012-12-31Completed
Optic Nerve Sheath Diameter (ONSD): A New Modality to Assess Postoperative Agitation After a Single Bolus of Dexmedetomidine Versus Nalbuphine in Children With Cleft Palate Repair [NCT04928391]Phase 390 participants (Anticipated)Interventional2021-06-20Recruiting
The Effect of Intravenous Nalbuphine on Postoperative Nausea and Vomiting With Intrathecal Morphine in Abdominoplastic Surgery. [NCT03786562]80 participants (Anticipated)Interventional2019-03-08Recruiting
Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Hypospadius Repair [NCT03476772]60 participants (Actual)Interventional2018-03-01Completed
Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy [NCT03288428]Phase 480 participants (Anticipated)Interventional2017-05-01Recruiting
Dexmedetomidine Versus Nalbuphine in Prevention of Emergence Agitation Following Adenotonsillectomy in Pediatrics [NCT04058899]Phase 1/Phase 2120 participants (Actual)Interventional2019-03-05Active, not recruiting
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants: A Single Center, Open-label, Prospective Study [NCT03059511]Phase 151 participants (Actual)Interventional2017-03-03Terminated(stopped due to We conclude that the doses we administered were safe, but too low. We plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal).)
Combination of Nalbuphine and Dexmedetomidine Versus Sufentanil and Dexmedetomidine on Patients After Laparoscopic Gastrointestinal Surgery: A Double-blind, Randomized, Controlled Clinical Study [NCT05445024]300 participants (Anticipated)Interventional2023-01-01Recruiting
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers. [NCT04256434]Phase 124 participants (Actual)Interventional2020-01-31Completed
Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Orbital Decompression [NCT03562611]63 participants (Actual)Interventional2018-06-08Completed
Intraperitoneal Instillation of Bupivacaine With Either Magnesium Sulphate or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy: a Prospective, Randomized, Double-blinded Trial. [NCT03393572]Phase 480 participants (Actual)Interventional2018-01-03Completed
Nalbuphine/Dexmedetomidine Versus Nalbuphine/Propofol Conscious Sedation for Cataract Extraction Under Topical Anaesthesia: A Double-Blind Randomized Trial [NCT03933280]Phase 2100 participants (Actual)Interventional2019-07-01Completed
The Efficacy Of Nalbuphine Versus Fentanyl As Additives To Bupivacaine In Spinal Anaesthesia For Internal FixationI Of Tibia [NCT03535792]50 participants (Actual)Interventional2017-11-04Completed
Efficacy of IV Lignocaine Versus IV Nalbuphine for Attenuation of Pressor Response Diring Laryngoscopy and Intubation in Patients Planned for Thyroid Surgery [NCT05298761]Early Phase 160 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Nalbuphine Versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section [NCT03918187]Phase 190 participants (Actual)Interventional2019-04-10Completed
The Effect of Low Dose Nalbuphine or Ketamine in the Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children Undergoing Tonsillectomy With or Without Adenoidectomy [NCT05176119]Phase 490 participants (Actual)Interventional2021-03-25Completed
Analgesic Efficacy and Safety of Nalbuphine Versus Morphine for Perioperative Tumor Ablation: a Randomized, Control, Multicentre Trial [NCT05073744]Phase 4316 participants (Anticipated)Interventional2021-09-05Recruiting
The 90% Effective Dose of Nalbuphine in Mechanical Ventilated Patients in the ICU [NCT03786887]Phase 460 participants (Anticipated)Interventional2018-10-24Recruiting
Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries Under Combined Spinal-epidural Anesthesia [NCT05041270]23 participants (Actual)Interventional2021-10-01Completed
Pharmacokinetic Study of Oral Nalbuphine in Normal Healthy Subjects [NCT00924079]60 participants (Anticipated)Interventional2008-09-30Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs [NCT00923000]Phase 150 participants (Anticipated)Interventional2008-12-31Recruiting
Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Hypospadias Repair [NCT02618876]60 participants (Actual)Interventional2015-11-30Completed
Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia [NCT02678585]106 participants (Actual)Interventional2015-12-31Completed
Analgesia Effects of Nalbuphine vs Sulfentanil in Patient-controlled Intravenous Analgesia After Cesarean Section [NCT02604797]80 participants (Anticipated)Interventional2016-01-31Not yet recruiting
A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management [NCT02193620]Phase 2/Phase 3106 participants (Actual)Interventional2013-04-30Completed
Study of Epidural Nalbuphine for Prevention of Epidural Morphine Induced Pruritus [NCT00707824]Phase 4165 participants (Actual)Interventional2000-06-30Completed
Non-anesthesiologist-administered Propofol is Not Related to a Higher Increase in Transcutaneous CO2 Pressure During the Flexible Bronchoscopy Compared to Guideline-based Sedation: A Randomized Controlled Trial [NCT02820051]91 participants (Actual)Interventional2014-02-28Completed
Comparison Between Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics During Sevoflurane Anesthesia: Prospective Randomized Controlled Clinical Trial [NCT05273671]Phase 4126 participants (Anticipated)Interventional2022-03-01Recruiting
The Efficacy of Long-Acting Nalbuphine Sebacate (Naldebain) for Pain Management After Knee Arthroplasty [NCT05266027]Phase 480 participants (Actual)Interventional2022-04-06Completed
Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough [NCT04030026]Phase 242 participants (Actual)Interventional2019-08-08Completed
Does Adding Nalbuphine to Intrathecal Morphine Reduce Morphine Induced Pruritus? A Randomized, Double Blind, Controlled Study. [NCT04589429]Phase 270 participants (Anticipated)Interventional2020-10-15Recruiting
Post-cesarean Section Analgesic Potency and Side Effects of Intrathecal Morphine and Nalbuphine [NCT02716129]Phase 280 participants (Actual)Interventional2016-07-31Completed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough [NCT05962151]Phase 260 participants (Anticipated)Interventional2023-11-30Recruiting
Intrathecal Midazolam is a Comparable Alternative to Fentanyl and Nalbuphine as Adjuvant to Bupivacaine in Spinal Anesthesia for Elective Cesarean Section; a Randomized Controlled Double-blind Trial [NCT04932083]100 participants (Actual)Interventional2021-06-20Completed
Effectiveness of Intrathecal Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in Patients Undergoing Transurethral Resection of the Prostate [NCT06153602]80 participants (Anticipated)Interventional2023-11-27Not yet recruiting
Epidural Steroids Combined With Intrathecal Nalbuphine: Analgesic and Side Effects Concept in Lower Abdominal Surgical Oncology Procedures [NCT03276325]70 participants (Actual)Interventional2017-09-15Completed
Comparison of Propofol-Nalbuphine and Propofol-Magnesium Sulphate Sedation for Patients Undergoing GIT Endoscopy [NCT05880459]Early Phase 160 participants (Anticipated)Interventional2023-08-31Not yet recruiting
Comparison of Systemic Nalbuphine Versus Intravenous Regional Anesthesia [NCT03150732]106 participants (Anticipated)Interventional2022-04-10Not yet recruiting
Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal Surgery [NCT05576675]Phase 34,342 participants (Actual)Interventional2018-05-01Completed
Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients [NCT00155233]Phase 4200 participants Interventional2005-01-31Recruiting
Analgesic Strategies in Newborns Receiving Prostaglandin Therapy [NCT00200590]30 participants (Anticipated)Interventional2003-12-31Terminated(stopped due to More important number of SAE in one arms)
Effect of Caudal Nalbuphine on Postoperative Emergence Agitation in Pediatrics Undergoing Infra-umbilical Surgeries [NCT05245721]Phase 180 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Effect of Epidural Dexmedetomidine VS Nalbuphine for Labor Analgesia [NCT05327088]Phase 264 participants (Actual)Interventional2021-09-12Completed
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus [NCT02143973]Phase 2/Phase 3167 participants (Actual)Interventional2014-09-30Completed
Nalbuphine for the Treatment of Opioid Induced Pruritus in Children [NCT00323154]Phase 3134 participants (Anticipated)Interventional2004-03-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients [NCT02174419]Phase 2/Phase 362 participants (Actual)Interventional2015-03-31Completed
A Study to Evaluate Pharmacokinetics of Nalbuphine Hydrochloride (10 mg/mL) After a Single Intravenous Administration in Healthy Volunteers Under Fasting Conditions [NCT03826316]Phase 414 participants (Actual)Interventional2018-01-15Completed
Effect of Kappa Opioid Agonist-Antagonists in the Heat/Capsaicin Sensitization Model [NCT00947284]3 participants (Actual)Interventional2010-01-31Terminated(stopped due to Experimental pain model didn't work as anticipated.)
Nalbuphine, Fentanyl and no Additive to Local Anaesthetic Mixture for Peribulbar Block During Posterior Segment Surgery in Adult Patients a Prospective Randomized Clinical Trial [NCT03824665]Phase 4120 participants (Actual)Interventional2019-02-05Completed
Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine Patient Controlled Analgesia (PCA) for Mucositis Pain in Pediatric Patients. A Prospective Randomized Double Blinded Clinical Trial [NCT03825887]Phase 380 participants (Actual)Interventional2018-02-01Completed
Dexmedetomidine Combined With Nalbuphine Advanced Analgesia on the Quality of Recovery After General Anesthesia in Elderly Patients [NCT05769530]Phase 4360 participants (Anticipated)Interventional2023-08-01Not yet recruiting
Comparative Study Between Intravenous Nalbuphine Versus Intravenous Dexmedetomidine for Conscious Sedation in Patients Undergoing Colonoscopy [NCT05689242]Phase 466 participants (Anticipated)Interventional2023-03-31Not yet recruiting
Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery a Randomized Controlled Study [NCT03436836]40 participants (Actual)Interventional2018-01-14Completed
A Study to Evaluate the Oral Abuse Potential of Nalbuphine Solution and Extended-Release Intact Tablets in Non-Dependent, Recreational Opioid Users [NCT04018664]Phase 156 participants (Actual)Interventional2018-05-29Completed
Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders [NCT00716807]46 participants (Actual)Interventional2008-01-31Terminated(stopped due to Unable to recruit a sufficient number of subjects.)
A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection vs. Bain®. Nalbuphine HCl IM Injection, in Healthy Volunteers [NCT02446301]Phase 112 participants (Actual)Interventional2015-01-31Completed
Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain, as Well as the Changes of the Postoperative Breathing Function Values, a Randomized, Controlled, Prospective Trial [NCT02445599]Phase 43 participants (Actual)Interventional2014-04-30Completed
Multimodal Postoperative Analgesia Using Accufuser for Multilevel Surgery for Obstructive Sleep Apnea (OSA) [NCT04483427]30 participants (Anticipated)Interventional2020-09-20Recruiting
A Phase 1, Open-Label, Non-Randomized, Parallel-Group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of Escalating Oral Doses of Nalbuphine Hydrochloride Extended Release Tablets in End-Stage Renal Disease Patients on Hem [NCT02373215]Phase 122 participants (Actual)Interventional2013-04-30Completed
Dexmedetomidine , Fentanyl or Nalbuphine As Additives to Epidural Bupivacaine for Labor Analgesia. A Double Blind Randomized Study. [NCT05746351]69 participants (Anticipated)Interventional2023-03-31Not yet recruiting
Adjuvants to Ultrasonic Guided Interscalene Block In Arthroscopic Rotator Cuff Repair; Morphine and/or Nalbuphine [NCT03034382]Phase 280 participants (Anticipated)Interventional2016-01-31Recruiting
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients [NCT02174432]Phase 2/Phase 336 participants (Actual)Interventional2015-08-15Completed
A Study of Nalbuphine Extended-release (NAL ER) Oral Tablets in Subjects With Impaired Hepatic Function Compared to Healthy Subjects and Exploratory Effect on Itch [NCT04020016]Phase 156 participants (Anticipated)Interventional2018-10-24Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus [NCT02143648]Phase 2/Phase 3373 participants (Actual)Interventional2014-06-30Completed
The Application of Transversus Abdominis Plane Block Plus Rectus Sheath Block in Peritoneal Dialysis Catheter Placement and Analgesia Based on Transversus Abdominis Plane Block Combined With κ Receptor Agonist and NSAID(Non-steroidal Anti-inflammatory Dru [NCT02984865]190 participants (Anticipated)Interventional2016-12-20Recruiting
The Effect of Analgesic Drugs on Respiratory Center [NCT04372342]Phase 450 participants (Anticipated)Interventional2019-05-01Recruiting
Dexmedetomidine Versus Nalbuphine as an Adjuvant to Intrathecal Bupivacaine in Lower Limb Surgeries [NCT05347173]60 participants (Anticipated)Interventional2022-06-21Recruiting
Analgesic Effect and Safety Analysis of Nalbuphine in ARDS Patients After Surgery [NCT06037330]Phase 460 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Effect of Intravenous Nalbuphine on Emergence Agitation in Children Undergoing Repair of Rupture Globe [NCT03470077]Phase 280 participants (Actual)Interventional2019-07-31Completed
Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Oculoplastic Surgery [NCT03422887]330 participants (Actual)Interventional2018-01-18Completed
Efficacy of Serratus Anterior Plane Block Using Bupivacaine Alone, Bupivacaine/ Magnesium Sulfate Versus Bupivacaine/ Nalbuphine for Thoracotomy: A Randomized, Double-Blinded Comparative Study. [NCT05565235]Phase 478 participants (Anticipated)Interventional2022-12-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02143648 (1) [back to overview]Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale
NCT02143973 (1) [back to overview]Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02174419 (1) [back to overview]Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale
NCT02174432 (1) [back to overview]Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)
NCT04018664 (1) [back to overview]To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).

Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale

The evaluation period was defined as the average itch score over weeks 7 and 8 following initiation of treatment. A negative change form baseline (Evaluation Period - Baseline) signified inmprovement. (NCT02143648)
Timeframe: 8 weeks

Interventionunits on a scale (Least Squares Mean)
Nalbuphine HCl ER 60mg-3.10
Nalbuphine HCl ER 120mg-3.49
Sugar Pill-2.80

[back to top]

Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs)

The number of participants reporting at least one TEAE of a particular body system and preferred term are reported (incidence) (NCT02143973)
Timeframe: 24 weeks

InterventionParticipants (Count of Participants)
Nalbuphine HCl ER133

[back to top]

Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale

The number of subjects who reported at least a 30% reduction from baseline to Week 10, expressed as a percentage of subjects in the particular arm/group who were evaluated, (NCT02174419)
Timeframe: Baseline, Week 10

Interventionpercentage of subjects (Number)
Nalbuphine HCl ER 90mg27.3
Nalbuphine HCl ER 180 mg44.4
Sugar Pill36.4

[back to top]

Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)

Incidence of adverse events is calculated based on events observed on or after the date of first dose, where incidence is defined as the number of subjects who reported one or more events of a particular adverse event divided by the number of subjects who received at least one dose of investigational product. Overall incidence is the proportion of subjects who had one or more adverse events of any type and nature pertains to the incidence of individual events coded by MedDRA nomenclature. An additional consideration was to evaluate incidence of adverse events by dose achieved but this was not done as subjects achieved a maximum dose during the study that varied and, per protocol, dosing could be modified per the investigator, during the course of this extension to TR03. In addition, TR03EXT involved a dose titration whereas events could have been reported well before a subject achieved some partciular dose level. Consequently, such a presentation would have been impossible to discern. (NCT02174432)
Timeframe: 50 weeks

InterventionParticipants (Count of Participants)
Nalbuphine HCl ER34

[back to top]

To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).

Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max (NCT04018664)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

Interventionmicrogram/L (Mean)
90 mg Nalbuphine HCl Solution21.70
120 mg Nalbuphine HCl Solution51.90
150 mg Nalbuphine HCl Solution68.67
180 mg Nalbuphine HCl Solution76.60
270 mg Nalbuphine HCl Solution56.00
Up to 405 mg Nalbuphine HCl Solution158.55
Up to 540 mg Nalbuphine HCl Solution196.83

[back to top]